Other Events ·
Cellectis S.A. announced a strategic transformation to become an in vivo gene editing company, focusing on two lead…
CLLSCellectis S.A.
Cellectis S.A. announced a strategic transformation to become an in vivo gene editing company, focusing on two lead programs: .HEAL-101 for severe hypertriglyceridemia and .HEAL-201 for severe hypercholesterolemia. The board approved exiting the development of lasme-cel and eti-cel due to a changing competitive landscape while continuing existing cell therapy partnerships with AstraZeneca, Allogene, Servier, and Iovance. This operational realignment aims to extend the company's cash runway into H2 2028. Preliminary Phase 1 data for .HEAL-101 is planned for H2 2027, and for .HEAL-201 in H1 2028. Cellectis operates in the biotechnology industry, developing genetic medicines using genome engineering platforms.